Your session is about to expire
← Back to Search
Glofitamab Combo for Lymphoma
Study Summary
This trial is testing a new cancer drug (glofitamab) in combination with other drugs that are already used to treat NHL and DLBCL. The goal is to find the best dose of glofitamab to give with these other drugs, and to see if the combination is safe and has any activity against the cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 1 trial • 23 Patients • NCT04313608Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My blood counts are within a healthy range.My kidneys are working well.I haven't taken any immune system drugs in the last 4 weeks or before starting my current treatment.I do not have severe nerve damage or a specific nerve disease.I have not had CAR T-cell therapy in the last 30 days.I have tuberculosis, whether it's active or not.I have not had anthracycline treatment or have not exceeded the safe lifetime dose.I can provide a biopsy sample between my last treatment and the start of the study medication.I had a stem cell transplant using my own cells within the last 100 days.I have not had an active or reactivated infection in the last 4 weeks.I've had side effects from previous immune therapy.I am allergic or react badly to parts of the immunochemotherapy treatment.I haven't had cancer treatment or been in a cancer study in the last 4 weeks.I have had a solid organ transplant.I have had a stem cell transplant from a donor.I have been diagnosed with progressive multifocal leukoencephalopathy.I have or had a brain or spinal cord disease.I am 18 years old or older.I have not had major surgery or a significant injury in the last 28 days.I have serious heart problems.I have not received a live vaccine in the last 4 weeks.I do not have any health issues that would make it unsafe for me to take a new drug.My NHL has come back or gotten worse after treatment with R or G.I have a type of lymphoma (DLBCL) that has not been treated and is likely to have CD20.I have a tumor that can be measured and is larger than 1.5 cm if it's in a lymph node or larger than 1.0 cm if it's outside of lymph nodes.Side effects from my previous cancer treatments are mild or gone.My liver is working well.I am taking more than 30 mg/day of prednisone or its equivalent.I have or had brain lymphoma.I do not have another cancer that could interfere with this study.I do not have any major health issues that could interfere with the study.
- Group 1: Part 2: DLBCL Pola-R-CHP
- Group 2: Part 1: Dose Escalation r/r NHL
- Group 3: Part 2: DLBCL G/R-CHOP
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the upper limit of participants in this trial?
"Affirmative. According to records stored on clinicaltrials.gov, this medical trial commenced on March 13th 2018 and is currently recruiting participants. It requires 172 patients from one location for completion of the study."
Are there any open enrollment opportunities for this trial?
"Affirmative, clinicaltrials.gov data alludes to this research study actively recruiting participants. This medicinal investigation was initially posted on March 13th 2018 and was updated most recently on November 4th 2022. 172 patients are being enrolled at a single site."
What potential risks can patients incur when taking Glofitamab?
"Glofitamab was given a score of 1 due to the fact that this is only Phase 1, meaning there is minimal evidence demonstrating its safety and efficacy."
What disorders does Glofitamab have the greatest efficacy for?
"Glofitamab is a useful therapy for numerous lung cancers, such as small cell carcinomas (SCLC). It can also be employed to treat thyroiditis and polyangium."
Have any other reports or investigations been conducted on Glofitamab?
"At present, 1558 trials are underway to assess the efficacy of Glofitamab. Of those studies, 330 have entered Phase 3 and 57052 locations worldwide are participating in these investigations. Most of this research is based out of Bethesda, Maryland."
Share this study with friends
Copy Link
Messenger